With drug costs continually escalating, health plans need to capture every available dollar to reduce their overall healthcare expenditures. One way to realize value is…
Plan sponsors are constantly waging a war on unnecessary drug spend and waste due to the inclusion of non-essential drugs on their PBM’s formulary or preferred…
For the past eight years, PSG’s Pharmacy Benefit Management Institute (PBMI) has produced original research focused on specialty drug benefit designs used by employers, unions,…
For the last eight years, PSG’s Pharmacy Benefit Management Institute (PBMI) has produced original research focused on specialty drug benefit designs used by employers, unions,…
Drug rebates are big business. According to life sciences analytics firm IQVIA, pharmaceutical manufacturers offered $153 billion in rebates and discounts in 2017. That’s double…
Rising prescription drug costs are a major concern in the United States, especially the effect these increases are having on individual patients who are on…
On January 31, the Trump Administration released a proposal that would require pharmacy benefit managers (PBMs) and insurers to pass through 100% of Medicare rebates to…
Controlling specialty drug costs and trends takes constant and careful vigilance. Yet many plan sponsors lack the tools or expertise to monitor integrated member spend…
The United States could face a serious shortage of both primary and specialty care physicians by 2030—up to 120,000, according to research from the Association of…
Specialty drug spend is a constant challenge for nearly all plan sponsors. One significant problem is managing high quantities on claims for specialty drugs covered…
Price gouging by pharmaceutical companies is an all-too-common problem that makes health plans and their members pay outrageous prices for previously affordable drugs. Perhaps the…